By Fineline Cube Xellar Biosystems, a U.S.-based pioneer in “AI + organ-on-a-chip” technology, announced the successful completion of a Series A financing round exceeding RMB 200 million (≈ USD 29 million). The round was exclusively led by China Life Investment, with continued backing from existing investors XtalPi, Yael Capital, and Legend Capital.
Funding & Strategic Allocation
| Use of Proceeds | Key Initiatives |
|---|---|
| Next-Gen Biological Infrastructure | Expand humanized organ-on-a-chip disease models across major therapeutic areas |
| Mechanistic Research Platform | Build a scalable, standardized system for high-throughput biological experimentation |
| Real Biological Data Engine | Continuously collect and curate high-fidelity, multimodal wet-lab data from 3D tissue models |
| AI Integration | Develop proprietary AI platform fusing computer vision, knowledge graphs, and multimodal modeling |
The company aims to establish a self-reinforcing “data generation → mechanism analysis → model training → experimental validation” flywheel, forming the core of its 3D Bio Intelligence system—a digital framework that combines real-world biological data with virtual cell simulations to dynamically represent and predict complex physiological and pathological processes.
Technology Vision
- Beyond 2D Models: Xellar’s humanized organ chips replicate tissue architecture, mechanical cues, and multicellular interactions absent in traditional cell cultures.
- Mechanism-First AI: Unlike black-box AI drug discovery firms, Xellar grounds its models in causal biological mechanisms, validated through iterative wet-lab feedback.
- Predictive Digital Twins: Long-term goal includes creating dynamic digital reconstructions of disease progression and treatment response for precision medicine applications.
Investor Confidence & Market Position
- China Life Investment’s Lead Role signals strong institutional trust in deep-tech biotech convergence and cross-border innovation.
- Backed by Top-Tier VCs: Support from XtalPi (AI-driven drug discovery leader) and Legend Capital underscores strategic alignment with next-gen R&D paradigms.
- Competitive Differentiation: Xellar is among the few globally integrating physical organ models, mechanistic biology, and generative AI into a unified discovery engine.
Forward-Looking Statements
This brief contains forward-looking statements regarding platform development, data collection, and AI capabilities. Actual outcomes depend on technical execution, regulatory compliance, and scientific validation.-Fineline Info & Tech